EyePoint Pharmaceuticals' stock dropped nearly 80% after its Phase 3 LUCIA trial for DURAVYU in wet age-related macular degeneration failed to meet the primary endpoint of non-inferiority to the control drug aflibercept. Despite missing this key goal, DURAVYU showed benefits like a 38% reduction in treatment burden. Legal firm Levi & Korsinsky is investigating potential securities law violations and encouraging affected investors to submit loss information for possible compensation. Investors who bought shares at inflated prices before the trial results may have legal rights, but no court appearances are required to participate in the investigation.
EyePoint Pharmaceuticals' recent trial results provide context for readers interested in health-sector stocks. For readers following this sector, here is Pluang's market snapshot as of Oct 20, 2026 04:11 WIB: out of 150 priced health-sector US stocks, 84 rose and 65 fell today. Among notable movers, Hinge Health Inc. (HNGE) rose 4.84% to USD 103.96 with a typical hold time of 5 days, Relay Therapeutics Inc. (RLAY) increased 4.79% to USD 17.06 with a 10-day hold, and DENTSPLY SIRONA Inc. (XRAY) gained 4.74% to USD 8.84 with a much longer typical hold time of 73 days.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
